Infectious Disease Expert Pardis Sabeti, M.D., Ph.D. Joins Board of The 221b Foundation
Retrieved on:
Thursday, September 15, 2022
Institute, Africa/Harvard School of Public Health Partnership for Cohort Research and Training, Precision medicine, Engineering, Department, COVID-19, Infection, FDA, Disease, Center, CRISPR, Immunology, Ministry, Severe acute respiratory syndrome coronavirus 2, Health in Nepal, MIT, Intellectual property, IP, Harvard University, Cancer, History, Organism, CEO, Technology, Biology, Pardis, Public health, Board of directors, Foundation, Lassa fever, Diagnosis, Howard Hughes Medical Institute, Open philanthropy (doctrine), Board, PCR, Broad Institute, Pharmaceutical industry, Vaccine, Management
"CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.
Key Points:
- "CRISPR is uniquely suited to meet the global need for accurate, rapid and affordable diagnostic testing," said Bryan DeChairo, board member of The 221b Foundation and president and CEO of Sherlock Biosciences.
- Pardis has been a fierce global health advocate for her entire career, and will provide invaluable counsel as we deliver on our mission."
- Through donations of equipment and resources, The 221b Foundation provided much needed support to help Nepal stem the spread of COVID-19 and bolster the countries testing strategy.
- The Foundation provides global health partners with access to Sherlock Biosciences' products and IP through distribution and licensing.